ORGO Stock Analysis: Buy, Sell, or Hold?
ORGO - Organogenesis Holdings Inc. Class A Common Stock
$2.57
0.22 (9.36%)
▲
5d:
+9.36%
30d:
+11.26%
90d:
-35.75%
BUY
MODERATE Confidence
Analysis Updated: May 1, 2026 12:00 AM ET
Earnings: May 07, 2026
4d
Smart Money Accumulation
ORGO is down 5.2% this week, but smart money is accumulating calls. Top strike: $2.5 2026-07-17 with 18 OI. Call ratio: 100% View Scanner →
Strength: 7.6/10
Get Alerted When ORGO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ORGO shows positive signals but monitor for confirmation. Market pricing in 22.0% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ORGO shows positive signals but monitor for confirmation. Market pricing in 22.0% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$7.60
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$4.72
45.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ORGO is currently trading at $2.57, which is considered extended relative to its 30-day fair value range of $2.30 to $2.49. From a valuation perspective, the stock is trading at a discount (Forward PE: 8.9) compared to its historical average (18.7). Remarkably, the market is currently pricing in an annual earnings decline of 22.0% over the next few years. This pessimistic expectation contrasts with the company's recent 555.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ORGO is in a strong downtrend. The price is approaching resistance at $2.56. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.4% recently.
Market Sentiment: ORGO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.00 (+211.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ORGO is in a strong downtrend. The price is approaching resistance at $2.56. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.4% recently.
Market Sentiment: ORGO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.00 (+211.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.30 -
$2.49
Company Quality Score
67/100
(BUY)
Volume Confirmation
MODERATE
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: Strong upward momentum (+9.4%)
- BULLISH: Trading 211.3% below Wall St target ($8.00)
Trading Range Analysis
30-Day Trading Range
$2.30 -
$2.49
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.28
Resistance Level
$2.57
Current Trend
Strong Downtrend
Technical data as of
May 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.86
Wall Street Target
$8.00
(+211.3%)
Revenue Growth (YoY)
78.1%
Earnings Growth (YoY)
555.2%
Profit Margin
6.6%
Valuation Discount vs History
-22.0% cheaper
PE vs Historical
8.9 vs 18.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-22.0%
(market-implied from PE analysis)
1-Year Target
$2.31
(-10%)
2-Year Target
$2.08
(-19%)
3-Year Target
$1.87
(-27%)
3-Yr Target (if PE normalizes)
(PE: 9→19)
$3.95
(+54%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 15.67 | Current EPS (TTM): $0.15
Bull Case
$5.00
(+95%)
Analyst growth 93.3%, PE expands to 17.2
Base Case
$4.54
(+77%)
Market implied 93.3%, PE stable at 15.7
Bear Case
$1.60
(-38%)
Severe decline -20.0%, PE contracts to 13.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.9 to 18.7
Stabilization Target:
$5.42
(+111.0%)
PE Expansion Potential:
+111.0%
Share & Embed Analysis
Last updated: May 02, 2026 4:16 PM ET
Data refreshes hourly during market hours. Next update: 5:16 PM
Data refreshes hourly during market hours. Next update: 5:16 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORGO showing a specific setup today?
Insider Activity (6 Months)
2
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Arthur S Leibowitz
BUY
5000 shares
2026-03-09
Michael Joseph Driscoll
BUY
10000 shares
2026-03-09
Glenn H Nussdorf
SELL
200000 shares
2025-12-16
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$186 | 65 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$150 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$94 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 63 BUY |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 57 HOLD |
